KG
CPRX

Kilter Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Kilter Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98K Buy
80
+14
+21% +$334 ﹤0.01% 956
2025
Q4 		$1.54K Buy
66
+3
+5% +$67 ﹤0.01% 895
2025
Q3 		$1.24K Buy
63
+15
+31% +$308 ﹤0.01% 816
2025
Q2 		$1.04K Buy
+48
New +$1.13K ﹤0.01% 814

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Kilter Group's CPRX Position: Q1 2026 in Review

Kilter Group increased its Catalyst Pharmaceutical (CPRX) stake by 21% in Q1 2026, buying an estimated $334 and bringing the position to 80 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Kilter Group first reported a position in CPRX in Q2 2025 and has held it in 4 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Kilter Group held 80 shares of Catalyst Pharmaceutical worth $1.98K as of Q1 2026.
  • Kilter Group bought 14 Catalyst Pharmaceutical shares in Q1 2026, an estimated $334.
  • Catalyst Pharmaceutical made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #956 holding.
  • Kilter Group first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.